GSTM1 and paroxysmal nocturnal hemoglobinuria: The results indicated that a substantial disease burden remains in patients with PNH receiving anti-C5 treatment, not only in patients with Hb levels below 10.5 g/dL but also in patients with Hb levels ≥ 10.5 g/dL, which resulted in low QoL and a great symptomatic impact on daily life.